关键词： Roche 丙肝药物 中国
2013年4月18日讯 /生物谷BIOON/ --Roche公司和其合作伙伴Ascletis准备大力促使其开发的治疗丙肝病毒药物danoprevir进入中国市场。Roche公司和Ascletis已经达成了一项关于开拓中国市场的协议，这项协议是建立在Roche公司治疗丙肝疗法--Pegasys销售额有所降低的背景下。（生物谷Bioon.com）
详细英文报道：
Roche ($RHHBY) and the biotech startup Ascletis have joined forces to advance Roche's experimental drug danoprevir for hepatitis C virus in the Chinese market. As Reuters reports, the deal comes as Roche sees a decline in sales of its injected interferon therapy Pegasys for hepatitis C, which many researchers want to treat with all-oral drugs. Under the new pact, Ascletis--which launched in 2011 with backing from Chinese real estate mogul Jinxing Qi--is expected to fund development and manufacturing of the drug in China and receive royalties and payments from the Swiss drug giant on potential sales of the protease inhibitor.
(责任编辑：zengchang)
